Development - A Mab A Case Study In Bioprocess
The primary article you are looking for is titled "A-Mab: A Case Study in Bioprocess Development," published on October 30, 2009, by the CMC Biotech Working Group International Society for Pharmaceutical Engineering (ISPE)
The purified Mab-X is now in a low-pH, high-salt buffer unsuitable for injection. The case study addresses two final challenges: A Mab A Case Study In Bioprocess Development
Monoclonal antibodies (mAbs) have become the cornerstone of modern biopharmaceuticals, treating everything from oncology and autoimmune disorders to infectious diseases. However, the journey from a hybridoma cell line to a commercially viable product is fraught with complexity. For every successful mAb on the market, there are hundreds of failed attempts—not due to lack of efficacy, but often due to poor bioprocess development. The primary article you are looking for is
11. Process Validation and Regulatory Considerations
Quality Risk Management (QRM):
The study employs tools like Failure Mode and Effects Analysis (FMEA) to assess how process parameters impact CQAs. For every successful mAb on the market, there
regulatory filing structure
To see the proposed in the study. a-mab-case-study-version.pdf - ISPE
Annual output:
50 kg → $3M direct manufacturing cost.